Keywords: ProMetic, Shenzhen Hepalink, R&D project, Equity investment, Asian market penetration

ProMetic signs deals with Shenzhen Hepalink Pharma to expand in Asia

Article | 18 October 2012

Canada’s ProMetic Life Sciences (TSX: PLI) has signed two strategic agreements with China-based Shenzhen Hepalink Pharmaceutical. The commercial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

ProMetic Life Sciences

Shenzhen Hepalink Pharmaceutical

Go to company listing